Ensuring adequate fluid intake is therefore particularly important during the dose-escalation phase of treatment
Epidemiological data demonstrates that sustained blood pressure decreases of this magnitude reduce stroke risk by approximately 35-40% and coronary heart disease risk by 20-25%
(2023) highlighted the ability of GLP-1 receptor agonists to address ageing-related diseases, such as diabetes, obesity, and kidney disease, potentially extending healthy lifespan
Neurobiological outcomes included changes in dopaminergic signaling, neuroinflammatory markers, circulating insulin and GLP-1 levels, and activation of reward-related brain regions
The initial phase of GLP-1 secretion occurs rapidly, within 1015 minutes of eating, even before nutrients reach the distal intestine where most L-cells reside
The tax savings from using an HSA or FSA for GLP-1 therapy depend on your marginal tax bracket and payroll deduction structure